Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results
for second quarter 2009 following the close of market on Tuesday, July
21, 2009.
On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time), Jay
Flatley, President and Chief Executive Officer, and Christian Henry,
Senior Vice President and Chief Financial Officer, will host a
conference call with analysts, investors, and other interested parties
to discuss financial and operating results.
Conference Call Details
The conference call will begin at 2:00pm Pacific Time (5:00pm Eastern
Time) on Tuesday, July 21, 2009. Interested parties may listen to the
call by dialing 1-800-638-5495 (passcode: 29875910), or if outside North
America, by dialing +1-617-614-3946 (passcode: 29875910). Individuals
may access the live teleconference under the "Corporate/Investor
Information" tab of Illumina's web site at www.illumina.com.
A replay of the conference call will be available from 5:00pm Pacific
Time (8:00pm Eastern Time) on July 21, 2009 through July 28, 2009 by
dialing 1-888-286-8010 (passcode: 85375226), or if outside North
America, by dialing +1-617-801-6888 (passcode: 85375226).
About Illumina
Illumina (www.illumina.com)
is a leading developer, manufacturer, and marketer of next-generation
life-science tools and integrated systems for the large-scale analysis
of genetic variation and biological function. Using our proprietary
technologies, we provide a comprehensive line of products and services
that currently serve the sequencing, genotyping, and gene expression
markets, and we expect to enter the market for molecular diagnostics.
Our customers include leading genomic research centers, pharmaceutical
companies, academic institutions, clinical research organizations, and
biotechnology companies. Our tools provide researchers around the world
with the performance, throughput, cost effectiveness, and flexibility
necessary to perform the billions of genetic tests needed to extract
valuable medical information from advances in genomics and proteomics.
We believe this information will enable researchers to correlate genetic
variation and biological function, which will enhance drug discovery and
clinical research, allow diseases to be detected earlier, and permit
better choices of drugs for individual patients.
This release contains forward-looking statements that involve risks and
uncertainties.
